Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Stryker CEO Kevin Lobo isn’t fazed by a proposal Medicare unveiled earlier this month that would bundle reimbursement payments for hip and knee replacement procedures.
The Centers for Medicare & Medicaid Services said July 9 that its 5-year “Comprehensive Care for Joint Replacement” program would involve more than 800 hospitals in 75 geographic areas, bundling payments for hip and knee replacements from hospital admission to 90 days after discharge. The payment would cover “all related items and services paid under Medicare Part A and Part B for all Medicare fee-for-service beneficiaries,” the government health insurer said. Read more
Medtronic asked the U.S. Supreme Court to review an appeals court’s decision upholding a patent infringement win for longtime spinal implant rival NuVasive Inc.
In April, the U.S. Court of Appeals for the Federal Circuit upheld without comment a U.S. Patent & Trademark Office decision that a NuVasive patent covering its is valid. Medtronic had argued that the PTO’s Patent Trial & Appeal Board broadened the patent during the validity battle with NuVasive, which took a re-examination and 2 hearings over the past 3 years. Although the board initially found for Medtronic’s broadness claim during the 1st hearing, it reversed itself during the 2nd hearing last year. Read more
An Italian state attorney in Milan moved to block the pending, $2.7 billion merger between Sorin Group and Cyberonics, seeking to prevent Sorin from dodging a $3.76 billion environmental lawsuit filed against its former corporate parent.
Sorin and Cyberonics, which announced the merger in February, plan to re-brand the combined company as LivaNova and re-incorporate in the U.K. Sorin’s shareholder’s OK’ed the deal in May, a month after it won approval from U.S. anti-trust regulators. Read more